| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
14,933 |
12,695 |
$913K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
7,095 |
6,183 |
$543K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
6,198 |
5,428 |
$328K |
| S9083 |
Global fee urgent care centers |
1,343 |
1,203 |
$156K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
2,511 |
2,163 |
$154K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
3,742 |
3,020 |
$112K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
12,252 |
4,987 |
$73K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
4,385 |
3,508 |
$68K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
1,597 |
1,416 |
$44K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
3,410 |
2,778 |
$21K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
369 |
276 |
$21K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
132 |
120 |
$7K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,398 |
867 |
$5K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
43 |
36 |
$2K |
| 99215 |
Prolong outpt/office vis |
12 |
12 |
$1K |
| 87807 |
|
174 |
145 |
$1K |
| 81003 |
|
251 |
213 |
$249.91 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
419 |
316 |
$216.16 |
| 99051 |
|
23 |
12 |
$128.40 |
| S9088 |
Services provided in an urgent care center (list in addition to code for service) |
48 |
46 |
$0.00 |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
30 |
15 |
$0.00 |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
14 |
12 |
$0.00 |